{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:15:32Z","timestamp":1785838532862,"version":"3.56.0"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Shenkang Hospital Development Center, China","award":["SHDC12020109"],"award-info":[{"award-number":["SHDC12020109"]}]},{"name":"Shanghai Shenkang Hospital Development Center, China","award":["21S11900500"],"award-info":[{"award-number":["21S11900500"]}]},{"name":"Shanghai Shenkang Hospital Development Center, China","award":["21S11905600"],"award-info":[{"award-number":["21S11905600"]}]},{"name":"Shanghai Municipal Science and Technology Commission, China","award":["SHDC12020109"],"award-info":[{"award-number":["SHDC12020109"]}]},{"name":"Shanghai Municipal Science and Technology Commission, China","award":["21S11900500"],"award-info":[{"award-number":["21S11900500"]}]},{"name":"Shanghai Municipal Science and Technology Commission, China","award":["21S11905600"],"award-info":[{"award-number":["21S11905600"]}]},{"name":"Shanghai Municipal Science and Technology Commission, China","award":["SHDC12020109"],"award-info":[{"award-number":["SHDC12020109"]}]},{"name":"Shanghai Municipal Science and Technology Commission, China","award":["21S11900500"],"award-info":[{"award-number":["21S11900500"]}]},{"name":"Shanghai Municipal Science and Technology Commission, China","award":["21S11905600"],"award-info":[{"award-number":["21S11905600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a vital global health problem. The characteristics are high morbidity, high mortality, difficulty in early diagnosis and insensitivity to chemotherapy. The main therapeutic schemes for treating HCC mainly include Tyrosine kinase inhibitors represented by sorafenib and lenvatinib. In recent years, immunotherapy for HCC has also achieved certain results. However, a great number of patients failed to benefit from systemic therapies. FAM50A belongs to the FAM50 family and can be used as a DNA-binding protein or transcription factor. It may take part in the splicing of RNA precursors. In studies of cancer, FAM50A has been demonstrated to participate in the progression of myeloid breast cancer and chronic lymphocytic leukemia. However, the effect of FAM50A on HCC is still unknown. In this study, we have demonstrated the cancer-promoting effects and diagnostic value of FAM50A in HCC using multiple databases and surgical samples. We identified the role of FAM50A in the tumor immune microenvironment (TIME) and immunotherapy efficacy in HCC. We also proved the effects of FAM50A on the malignancy of HCC in vitro and in vivo. In conclusion, we confirmed that FAM50A is an important proto-oncogene in HCC. FAM50A acts as a diagnostic marker, immunomodulator and therapeutic target for HCC.<\/jats:p>","DOI":"10.3390\/ijms24043217","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T01:56:48Z","timestamp":1675735008000},"page":"3217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-6708","authenticated-orcid":false,"given":"Xudong","family":"Xie","sequence":"first","affiliation":[{"name":"Liver Diseases Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Liver Diseases Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Tao","sequence":"additional","affiliation":[{"name":"Research Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-1414","authenticated-orcid":false,"given":"Mingsheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Research Center for Biomaterials, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fei","sequence":"additional","affiliation":[{"name":"Liver Diseases Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-4141","authenticated-orcid":false,"given":"Qunling","family":"Yang","sequence":"additional","affiliation":[{"name":"Liver Diseases Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Huang","sequence":"additional","affiliation":[{"name":"Liver Diseases Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Liver Diseases Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized Controlled Trial of Screening for Hepatocellular Carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1200\/JCO.2011.38.2697","article-title":"Plasma Microrna Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma","volume":"29","author":"Zhou","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"Galad Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients with Nonalcoholic Steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","first-page":"43","article-title":"Racial Disparities in Treatment and Survival of Patients with Hepatocellular Carcinoma in the United States","volume":"5","author":"Xu","year":"2016","journal-title":"Hepatobil. Surg. Nutr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17474124.2018.1453806","article-title":"Conditional Survival of Patients with Hepatocellular Carcinoma: Results From the Surveillance, Epidemiology, and End Results Registry","volume":"12","author":"Zhang","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase Iii Randomised, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib Versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable Or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase Ii-Iii Trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab Or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab Versus Chemotherapy for Pd-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"Fda Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable Or Metastatic Hepatocellular Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab Plus a Bevacizumab Biosimilar (Ibi305) Versus Sorafenib in Unresectable Hepatocellular Carcinoma (Orient-32): A Randomised, Open-Label, Phase 2-3 Study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of Adverse Events Associated with Tyrosine Kinase Inhibitors: Improving Outcomes for Patients with Hepatocellular Carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"794099","DOI":"10.3389\/fimmu.2021.794099","article-title":"Correlation between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated with Immune Checkpoint Inhibitors","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"752725","DOI":"10.3389\/fonc.2021.752725","article-title":"Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials","volume":"11","author":"Mou","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Oura, K., Morishita, A., Tani, J., and Masaki, T. (2021). Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115801"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"BSR20201920","DOI":"10.1042\/BSR20201920","article-title":"Prognostic and Immunological Role of Fam20C in Pan-Cancer","volume":"41","author":"Liu","year":"2021","journal-title":"Biosci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12958-018-0412-4","article-title":"Identification of Mrnas Related to Endometrium Function Regulated by Lncrna Cd36-005 in Rat Endometrial Stromal Cells","volume":"16","author":"Zhang","year":"2018","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1746-1596-7-161","article-title":"Immunohistochemical Analysis of Medullary Breast Carcinoma Autoantigens in Different Histological Types of Breast Carcinomas","volume":"7","author":"Kostianets","year":"2012","journal-title":"Diagn. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/1078-0432.CCR-15-3103","article-title":"A Quantitative Analysis of Subclonal and Clonal Gene Mutations Before and After Therapy in Chronic Lymphocytic Leukemia","volume":"22","author":"Amin","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15175","DOI":"10.1038\/s41598-021-94701-8","article-title":"Integrative Analysis Reveals the Prognostic Value and Functions of Splicing Factors Implicated in Hepatocellular Carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","article-title":"International Trends in Hepatocellular Carcinoma Incidence, 1978\u20132012","volume":"147","author":"Petrick","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","article-title":"Incidence and Predictors of Hepatocellular Carcinoma in Caucasian Chronic Hepatitis B Patients Receiving Entecavir Or Tenofovir","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B Vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00046-19","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for Hcv Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global Burden of Nafld and Nash: Trends, Predictions, Risk Factors and Prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global Epidemiology of Nafld-Related Hcc: Trends, Predictions, Risk Factors and Prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/MCG.0b013e3182a030c4","article-title":"The Association between Metabolic Syndrome and Hepatocellular Carcinoma: Systemic Review and Meta-Analysis","volume":"48","author":"Jinjuvadia","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_35","unstructured":"(2020). Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","article-title":"Future of Hepatocellular Carcinoma Incidence in the United States Forecast through 2030","volume":"34","author":"Petrick","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-021-01466-9","article-title":"Crispr Screens Uncover Protective Effect of Pstk as a Regulator of Chemotherapy-Induced Ferroptosis in Hepatocellular Carcinoma","volume":"21","author":"Chen","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"669928","DOI":"10.3389\/fgene.2021.669928","article-title":"Elevated Expression of Pdzd11 is Associated with Poor Prognosis and Immune Infiltrates in Hepatocellular Carcinoma","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An Integrated Tcga Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"Timer: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2144\/000112776","article-title":"Twenty-Five Years of Quantitative Pcr for Gene Expression Analysis","volume":"44","author":"VanGuilder","year":"2008","journal-title":"Biotechniques"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:25:52Z","timestamp":1760120752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043217"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043217","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]}}}